The FDA has approved the use of Abraxane for first line treatment of non small cell lung cancer (NSCLC) in combination with carboplatin. This approval is for patients who have locally advanced or metastatic NSCL who are not candidates for curative surgery or radiation. Abraxane is already approved for treatment of metastatic breast cancer. What are other approved therapies for non small cell lung cancer?

For more information see Huffington Post.